LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 36

Search options

  1. Article ; Online: Antimicrobial Strategies for Cystic Fibrosis.

    Møller, Rikke / Pressler, Tacjana / Qvist, Tavs

    Seminars in respiratory and critical care medicine

    2022  Volume 44, Issue 2, Page(s) 297–306

    Abstract: Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication ... ...

    Abstract Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with
    MeSH term(s) Humans ; Cystic Fibrosis/complications ; Cystic Fibrosis/drug therapy ; Cystic Fibrosis/microbiology ; Pseudomonas Infections/drug therapy ; Anti-Bacterial Agents/therapeutic use ; Administration, Inhalation ; Pseudomonas aeruginosa
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2022-12-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1183617-9
    ISSN 1098-9048 ; 1069-3424
    ISSN (online) 1098-9048
    ISSN 1069-3424
    DOI 10.1055/s-0042-1758733
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1555: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Antimicrobial Strategies for Cystic Fibrosis

    Møller, Rikke / Pressler, Tacjana / Qvist, Tavs

    Seminars in Respiratory and Critical Care Medicine

    (Cystic Fibrosis)

    2022  Volume 44, Issue 02, Page(s) 297–306

    Abstract: Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication ... ...

    Series title Cystic Fibrosis
    Abstract Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.
    Keywords nontuberculous mycobacteria ; evidence ; eradication ; inhaled antibiotics
    Language English
    Publishing date 2022-12-19
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 1183617-9
    ISSN 1098-9048 ; 1069-3424
    ISSN (online) 1098-9048
    ISSN 1069-3424
    DOI 10.1055/s-0042-1758733
    Database Thieme publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1555: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Achromobacter

    Crone, Cornelia Geisler / Rezahosseini, Omid / Schultz, Hans Henrik Lawaetz / Qvist, Tavs / Johansen, Helle Krogh / Nielsen, Susanne Dam / Perch, Michael

    Pathogens (Basel, Switzerland)

    2022  Volume 11, Issue 2

    Abstract: ... ...

    Abstract Achromobacter
    Language English
    Publishing date 2022-01-28
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2695572-6
    ISSN 2076-0817
    ISSN 2076-0817
    DOI 10.3390/pathogens11020181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.

    Katzenstein, Terese L / Faurholt-Jepsen, Daniel / Qvist, Tavs / Jensen, Peter Østrup / Pressler, Tacjana / Johansen, Helle Krogh / Kolpen, Mette

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

    2023  Volume 131, Issue 8, Page(s) 419–425

    Abstract: Ceftolozane-tazobactam is a new β-lactam/β-lactamase inhibitor combination approved by the U.S. Food and Drug Administration in 2019 for the treatment of hospital-acquired and ventilator-associated pneumonia. The combination is a particularly potent ... ...

    Abstract Ceftolozane-tazobactam is a new β-lactam/β-lactamase inhibitor combination approved by the U.S. Food and Drug Administration in 2019 for the treatment of hospital-acquired and ventilator-associated pneumonia. The combination is a particularly potent inhibitor of penicillin-binding proteins with higher affinity than other β-lactam agents. Persons with cystic fibrosis (pwCF) often harbour resistant Gram-negative bacteria in the airways and need antibiotics to prevent declining lung function. To test whether the introduction of ceftolozane-tazobactam in the period 2015-2020 led to a bacterial population level increase in cephalosporin resistance in a Danish CF population. In vitro, activity of ceftolozane-tazobactam was evaluated by susceptibility testing of clinical Pseudomonas aeruginosa isolated from pwCF from January 1, 2015, to June 1, 2020. Six thousand three hundred thirty two isolates collected from 210 adult pwCF were included. Thirty pwCF were treated with ceftolozane-tazobactam at least once. Ceftolozane-tazobactam exposure did not increase cephalosporin resistance on an individual or population level. However, resistance to ceftolozane-tazobactam was recorded despite no prior exposure in four pwCF. Compared to ceftazidime, ceftolozane-tazobactam had a better in vitro activity on P. aeruginosa. The percentage of non-mucoid P. aeruginosa isolates susceptible to ceftolozane-tazobactam were higher or equal to 5 other β-lactams. Ceftolozane-tazobactam expands the armamentaria against P. aeruginosa with acceptable levels for a selection of drug resistance.
    MeSH term(s) Humans ; Adult ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; beta-Lactamase Inhibitors/pharmacology ; beta-Lactamase Inhibitors/therapeutic use ; Pseudomonas aeruginosa ; Cystic Fibrosis/microbiology ; Cephalosporinase/pharmacology ; Cephalosporinase/therapeutic use ; Drug Resistance, Bacterial ; Cephalosporins/pharmacology ; Cephalosporins/therapeutic use ; Tazobactam/pharmacology ; Tazobactam/therapeutic use ; Monobactams/pharmacology ; Monobactams/therapeutic use ; Microbial Sensitivity Tests ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/microbiology ; Drug Resistance, Multiple, Bacterial
    Chemical Substances ceftolozane (37A4IES95Q) ; Anti-Bacterial Agents ; beta-Lactamase Inhibitors ; Cephalosporinase (EC 3.5.2.-) ; Cephalosporins ; ceftolozane, tazobactam drug combination ; Tazobactam (SE10G96M8W) ; Monobactams
    Language English
    Publishing date 2023-06-09
    Publishing country Denmark
    Document type Journal Article
    ZDB-ID 93340-5
    ISSN 1600-0463 ; 0903-4641
    ISSN (online) 1600-0463
    ISSN 0903-4641
    DOI 10.1111/apm.13331
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.73: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: At-Risk Groups of Men Who Have Sex With Men Can Be Reached Through Community-Based HIV Testing in Denmark.

    Munck, Holger Nordstr M / Qvist, Tavs / Helleberg, Marie / Kaye, Per Slaaen / Pichon, Francois / Cowan, Susan

    AIDS education and prevention : official publication of the International Society for AIDS Education

    2021  Volume 33, Issue 5, Page(s) 439–449

    Abstract: This study evaluates whether the community-based HIV testing clinic Checkpoint could reach at-risk groups of men who have sex with men (MSM) and link patients to care. A prospective observational study of all Checkpoint visits during 2013-2016 and a ... ...

    Abstract This study evaluates whether the community-based HIV testing clinic Checkpoint could reach at-risk groups of men who have sex with men (MSM) and link patients to care. A prospective observational study of all Checkpoint visits during 2013-2016 and a retrospective registry study of all MSM diagnosed with HIV in Denmark during the same period were conducted. One percent of the 9,074 tests in Checkpoint were HIV-positive, accounting for 19% of all new HIV diagnoses among MSM in Denmark. Checkpoint testers reported frequent condomless anal sex. Two percent of migrant Checkpoint testers were HIV-positive compared to 1 % among Danish MSM. HIV-positive MSM identified through Checkpoint were significantly younger, more of them were migrant, and a smaller proportion were late testers compared to those testing through the conventional health care system. Checkpoint reaches at-risk populations of MSM and links patients successfully to care.
    MeSH term(s) Denmark/epidemiology ; HIV Infections/prevention & control ; HIV Testing ; Homosexuality, Male ; Humans ; Male ; Mass Screening ; Retrospective Studies ; Sexual Behavior ; Sexual and Gender Minorities
    Language English
    Publishing date 2021-08-09
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 1075448-9
    ISSN 1943-2755 ; 0899-9546
    ISSN (online) 1943-2755
    ISSN 0899-9546
    DOI 10.1521/aeap.2021.33.5.1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3231: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Close monitoring and early intervention: management principles for cystic fibrosis in Denmark.

    Qvist, Tavs / Nielsen, Bibi Uhre / Olesen, Hanne Vebert / Mathiesen, Inger Hee Mabuza / Faurholt-Jepsen, Daniel / Katzenstein, Terese L / Helweg-Larsen, Jannik / Rönsholt, Frederikke / Jeppesen, Majbritt / Olsen, Mette Frahm / Buchvald, Frederik Fouirnaies / Nielsen, Kim Gjerum / Jensen-Fangel, Søren / Pressler, Tania / Skov, Marianne

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

    2024  Volume 132, Issue 4, Page(s) 223–235

    Abstract: Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has ... ...

    Abstract Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.
    MeSH term(s) Humans ; Cystic Fibrosis/complications ; Europe ; Anti-Infective Agents/therapeutic use ; Denmark
    Chemical Substances Anti-Infective Agents
    Language English
    Publishing date 2024-01-24
    Publishing country Denmark
    Document type Journal Article ; Review
    ZDB-ID 93340-5
    ISSN 1600-0463 ; 0903-4641
    ISSN (online) 1600-0463
    ISSN 0903-4641
    DOI 10.1111/apm.13375
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.73: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Achromobacter spp. in a Cohort of Non-Selected Pre- and Post-Lung Transplant Recipients

    Cornelia Geisler Crone / Omid Rezahosseini / Hans Henrik Lawaetz Schultz / Tavs Qvist / Helle Krogh Johansen / Susanne Dam Nielsen / Michael Perch

    Pathogens, Vol 11, Iss 181, p

    2022  Volume 181

    Abstract: Achromobacter is an opportunistic pathogen that mainly causes chronic lung infections in cystic fibrosis (CF) patients and is associated with increased mortality. Little is known about Achromobacter spp. in the lung transplant recipient (LTXr) population. ...

    Abstract Achromobacter is an opportunistic pathogen that mainly causes chronic lung infections in cystic fibrosis (CF) patients and is associated with increased mortality. Little is known about Achromobacter spp. in the lung transplant recipient (LTXr) population. We aimed at describing rates of Achromobacter spp. infection in LTXr prior to, in relation to, and after transplantation, as well as all-cause mortality proportion in infected and uninfected LTXr. We included 288 adult LTXr who underwent lung transplantation (LTX) between 1 January 2010 and 31 December 2019 in Denmark. Bronchoalveolar lavage was performed at regular intervals starting two weeks after transplantation. Positive cultures of Achromobacter spp. were identified in nationwide microbiology registries, and infections were categorized as persistent or transient, according to the proportion of positive cultures. A total of 11 of the 288 LTXr had transient ( n = 7) or persistent ( n = 4) Achromobacter spp. infection after LTX; CF was the underlying disease in 9 out of 11 LTXr. Three out of the four patients, with persistent infection after LTX, also had persistent infection before LTX. The cumulative incidence of the first episode of infection one year after LTX was 3.8% (95% CI: 1.6–6.0). The incidence rates of transient and persistent infection in the first year after LTX were 27 (12–53) and 15 (5–37) per 1000 person-years of follow-up, respectively. The all-cause mortality proportion one year after LTX was 27% in the Achromobacter spp. infected patients and 12% in the uninfected patients ( p = 0.114). Achromobacter spp. mainly affected LTXr with CF as the underlying disease and was rare in non-CF LTXr. Larger studies are needed to assess long-term outcomes of Achromobacter spp. in LTXr.
    Keywords Achromobacter ; lung transplantation ; solid organ transplantation ; cystic fibrosis ; incidence ; mortality ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2022-01-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Adaptive Immune Response to

    Mauch, Renan Marrichi / Jensen, Peter Østrup / Qvist, Tavs / Kolpen, Mette / Moser, Claus / Pressler, Tacjana / Nolasco da Silva, Marcos Tadeu / Høiby, Niels

    Frontiers in cellular and infection microbiology

    2022  Volume 12, Page(s) 858398

    Abstract: Background: We aimed to characterise the adaptive immune response to : Methods: In this cross-sectional analysis, peripheral blood mononuclear cells (PBMC) from CF patients with MABSC (CF/MABSC, n=12), MAC infection history (CF/MAC, n=5), no NTM ... ...

    Abstract Background: We aimed to characterise the adaptive immune response to
    Methods: In this cross-sectional analysis, peripheral blood mononuclear cells (PBMC) from CF patients with MABSC (CF/MABSC, n=12), MAC infection history (CF/MAC, n=5), no NTM history (CF/NTM-, n=15), BCG-vaccinated (C/BCG+, n=9) and non-vaccinated controls (C/BCG-, n=8) were cultured for four days under stimulation with an in-house MABSC lysate and we used flow cytometry to assess lymphocyte proliferation (given by lymphoblast formation) and immunophenotypes. Cytokine production was assessed after overnight whole blood stimulation with the same lysate, and anti-MABSC IgG levels were measured in plasma from non-stimulated blood.
    Results: All CF/MABSC patients had increased CD3+ and CD19+ lymphoblast formation upon PBMC stimulation with MABSC lysate. There was a higher rate of CD3+ than CD19+ lymphoblasts, predominance of CD4+ over CD8+ lymphoblasts, IFN-γ, TNF-α and IL-2 production, low production of the Th17-associated IL-17, and discrete or no production of Th2/B cell-associated cytokines soluble CD40 ligand (CD40L), IL-4 and IL-5, indicating a Th1-dominated phenotype and infection restricted to the lungs. A similar pattern was seen in C/BCG+ controls, and CF/MAC patients, pointing to cross-reactivity. MABSC-IgG levels were higher in CF/MABSC patients than in both control groups, but not CF/NTM- patients, most of whom also had CD3+ and/or CD19+ lymphoblast formation upon PBMC stimulation, indicating previous exposure, subclinical or latent infection with MABSC or other NTM.
    Conclusion: The anti-MABSC immune response is Th1-skewed and underlines the cross-reactivity in the anti-mycobacterial immune response. The results, together with published clinical observations, indicate that BCG vaccination may cross-react against NTM in CF patients, and this should be investigated. Due to cross-reactivity, it would also be interesting to investigate whether a combination of MABSC-induced cytokine production by blood cells and anti-MABSC IgG measurement can be useful for identifying latent or subclinical infection both with MABSC and other NTM in CF patients.
    MeSH term(s) Adaptive Immunity ; BCG Vaccine ; Cross-Sectional Studies ; Cystic Fibrosis/microbiology ; Cytokines ; Humans ; Immunoglobulin G ; Leukocytes, Mononuclear ; Mycobacterium Infections, Nontuberculous/microbiology ; Mycobacterium abscessus
    Chemical Substances BCG Vaccine ; Cytokines ; Immunoglobulin G
    Language English
    Publishing date 2022-04-20
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2619676-1
    ISSN 2235-2988 ; 2235-2988
    ISSN (online) 2235-2988
    ISSN 2235-2988
    DOI 10.3389/fcimb.2022.858398
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Education, employment, and income among people living with cystic fibrosis across three decades - A matched cohort study using Danish health registries.

    Jensen, Camilla Bjørn / Jensen, Kristoffer Jarlov / Pressler, Tacjana / Katzenstein, Terese L / Skov, Marianne / Qvist, Tavs / Olsen, Mette Frahm / Jeppesen, Majbritt / Jensen-Fangel, Søren / Olesen, Hanne Vebert / Reuter, Simon Bertram / Pedersen, Hans Kristian Råket / Wang, Joanna Nan / Michalopoulos, Steven / McGarry, Lisa / Wöhling, Heike / Petersen, Janne / Jimenez-Solem, Espen

    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

    2024  

    Abstract: Background: Past and ongoing advancements in cystic fibrosis (CF) care warrant long-term analysis of the societal impact of the condition. This study aims to evaluate changes in key socioeconomic factors across three decades among people living with CF ( ...

    Abstract Background: Past and ongoing advancements in cystic fibrosis (CF) care warrant long-term analysis of the societal impact of the condition. This study aims to evaluate changes in key socioeconomic factors across three decades among people living with CF (pwCF), compared with both the general population and an early-onset chronic disease population.
    Methods: This nationwide, registry-based, matched cohort study included all pwCF ≥ 18 years in Denmark in the years 1990, 2000, 2010, and 2018. Each person living with CF was matched to five individuals in the general population and five individuals living with type 1 diabetes or juvenile arthritis based on age, sex, and municipality.
    Results: The Danish adult CF population increased nearly fourfold from 88 in 1990 to 331 in 2018, and mean age increased by ten years. The educational level of pwCF was similar to the two comparator cohorts, while pwCF were less often in employment and more often permanently outside the labor force. Personal and household income levels of the CF cohort were higher than those of the comparator cohorts.
    Conclusions: The disadvantage in employment for pwCF remained, but, over time, the societal profiles of the one-year CF cohorts increasingly converged with those of the comparator cohorts, indicative of improved clinical management, extended life expectancy, and the supportive role of the Danish welfare system in reducing health inequalities. Further research should be done to evaluate the effects of the newly introduced modulator therapies on employment, considering the broader societal impact and impact on quality of life.
    Language English
    Publishing date 2024-03-14
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2084724-5
    ISSN 1873-5010 ; 1569-1993
    ISSN (online) 1873-5010
    ISSN 1569-1993
    DOI 10.1016/j.jcf.2024.03.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6028: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 459: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Mycobacterium brisbanense lung infection facilitated by steroid induced adrenal insufficiency.

    Gynthersen, Rosa / Qvist, Tavs / Andersen, Åse B / Katzenstein, Terese L

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

    2018  Volume 127, Issue 2, Page(s) 106–108

    Abstract: Mycobacterium brisbanense is rapid-growing nontuberculous mycobacteria. It was first described in 2004 as a human pathogen and only one case report has previously been published. We report a case of M. brisbanense infection in a young man with asthma, ... ...

    Abstract Mycobacterium brisbanense is rapid-growing nontuberculous mycobacteria. It was first described in 2004 as a human pathogen and only one case report has previously been published. We report a case of M. brisbanense infection in a young man with asthma, recurrent lung infections and secondary adrenal insufficiency induced by inhalation steroids and itraconazole use. The mycobacterial infection was successfully treated with a long-term multidrug regimen.
    MeSH term(s) Adrenal Insufficiency/pathology ; Adult ; Amikacin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Clarithromycin/therapeutic use ; Drug Therapy, Combination ; Humans ; Male ; Moxifloxacin/therapeutic use ; Mycobacterium Infections, Nontuberculous/drug therapy ; Mycobacterium Infections, Nontuberculous/microbiology ; Nontuberculous Mycobacteria/isolation & purification ; Respiratory Tract Infections/drug therapy ; Respiratory Tract Infections/microbiology ; Sputum/microbiology
    Chemical Substances Anti-Bacterial Agents ; Amikacin (84319SGC3C) ; Clarithromycin (H1250JIK0A) ; Moxifloxacin (U188XYD42P)
    Language English
    Publishing date 2018-12-25
    Publishing country Denmark
    Document type Case Reports
    ZDB-ID 93340-5
    ISSN 1600-0463 ; 0903-4641
    ISSN (online) 1600-0463
    ISSN 0903-4641
    DOI 10.1111/apm.12911
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.73: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top